Molecular imaging is a technique used to visualise and study molecular and cellular processes. When coupled with the use of recombinant antibodies, engineered specifically for targeting cardiovascular markers, molecular imaging becomes even more powerful. Our team has developed a range of recombinant antibodies that allow the targeting of inflamed endothelial cells, activated platelets and monocytes, as well as the coagulation system. These recombinant antibodies exhibit high affinity and selectivity, reduced immunogenicity, and can be conjugated with different imaging agents for multimodal imaging (MRI, PET, ultrasound and fluorescence imaging). This combination enhances diagnostic accuracy, facilitates precise imaging of disease processes, and contributes to the development of targeted therapies, ultimately improving patient outcomes in cardiovascular diseases. The diseases that we investigate within our lab include atherosclerosis, thrombosis, myocardial infarction, and other chronic inflammatory diseases (rheumatoid arthritis and multiple sclerosis).
In our laboratory, we place a significant focus on the biotechnological development of these antibodies and contrast particles because we recognise the crucial translational potential of these advancements in the field.